GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (NAS:COO) » Definitions » Ending Cash Position

The Cooper (The Cooper) Ending Cash Position : $135 Mil (As of Jan. 2024)


View and export this data going back to 1983. Start your Free Trial

What is The Cooper Ending Cash Position?

The Cooper's Ending Cash Position for the quarter that ended in Jan. 2024 was $135 Mil.

The Cooper's quarterly Ending Cash Position increased from Jul. 2023 ($118 Mil) to Oct. 2023 ($121 Mil) and increased from Oct. 2023 ($121 Mil) to Jan. 2024 ($135 Mil).

The Cooper's annual Ending Cash Position increased from Oct. 2021 ($97 Mil) to Oct. 2022 ($139 Mil) but then declined from Oct. 2022 ($139 Mil) to Oct. 2023 ($121 Mil).

The Cooper Ending Cash Position Historical Data

The historical data trend for The Cooper's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper Ending Cash Position Chart

The Cooper Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.50 116.80 96.60 138.60 120.90

The Cooper Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118.50 112.10 117.50 120.90 135.30

The Cooper Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

The Cooper's Ending Cash Position for the fiscal year that ended in Oct. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=138.6+-17.7
=121

The Cooper's Ending Cash Position for the quarter that ended in Jan. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=120.9+14.4
=135

The Cooper Ending Cash Position Related Terms

Thank you for viewing the detailed overview of The Cooper's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

The Cooper (The Cooper) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (NAS:COO) » Definitions » Ending Cash Position
Comparable Companies
BAX HOLX WST RMD TFX RGEN ATR STVN XRAY MMSI ISRG XPAR:EL BDX TSE:7741 XSWX:ALC OCSE:COLO B XPAR:DIM TSE:4543 XSWX:STMN TSE:7733
Traded in Other Exchanges
COO:Mexico CP6:Germany C1OO34:Brazil
Address
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583
Website
https://www.coopercos.com
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.
Executives
Gary S Petersmeyer director 3400 CENTRAL AVENUE, SANTA CLARA CA 95051
Robert S Weiss director, officer: EVP and CFO 6140 STANERIDGE MALL RES #590, PLEASSANTON CA 94503
Agostino Ricupati officer: Sr. VP, Finance & Tax C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Warner Gerard H Iii officer: President, CooperVision, Inc. C/O COOPER COMPANIES INC., 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Cynthia L Lucchese director 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Nicholas Khadder officer: VP, General Counsel & Corp Sec 2836 JOHNSON AVENUE, ALAMEDA CA 94501
Daniel G Mcbride officer: VP and Senior Counsel 5 EL CORTE, ORINDA CA 94563
Brian G Andrews officer: Treasurer 4300A 17TH STREET, SAN FRANCISCO CA 94114
Maria Rivas director C/O MEDIDATA SOLUTIONS, INC., 350 HUDSON STREET, 9TH FLOOR, NEW YORK NY 10014
White Albert G Iii officer: VP & Treasurer 6790, SPRINGDALE COURT, VICTOR NY 14564
Teresa S Madden director 414 NICOLLET MALL, MINNEAPOLIS MN 55401
Robert D Auerbach officer: President, CSI C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Holly R Sheffield officer: EVP, CSO C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Mark J Drury officer: VP, General Counsel & Sec. C/O COOPERCOMPANIES, 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583